Glenmark Specialty
-
Jiangsu Alphamab Biopharmaceuticals, 3D Medicines (Beijing), Glenmark in licensing agreement
Glenmark will be responsible for further developing, registering and commercialising Envafolimab in India, Asia Pacific, Middle East and Africa, Russia,…
Read More » -
Glenmark receives US FDA nod for GRC 54276 to treat advanced solid tumours and lymphomas
GRC 54276 is an orally available, small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor Glenmark Specialty, the subsidiary of Glenmark Pharmaceuticals,…
Read More » -
Bausch Health, Glenmark bags RYALTRIS approval in Canada
RYALTRIS treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged sixyears…
Read More » -
Glenmark Specialty Switzerland receives NDA approval for Ryaltris Nasal Spray
Ryaltris will be marketed and distributed in the US by Hikma Specialty USA Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical…
Read More »